 |
 |
|
|
|
| Omeprazole |
 |
| Omeprazole |
 |
Omeprazole
CAS: 73590-58-6
Assay: 98.5% min. CP
Packing: 20Kg/cardboard drum
MF: C17H19N3O3S
MW: 345.42
Character: White Crystalline Solid. mp 156°C. solubility H2O: 0.5 mg/mL
Usage: Binds covalently to proton pump. It inhibits gastric secretion. Used as an anttiulcerative pharmaceutical raw materials.
Biological Activity: H + ,K + -ATPase inhibitor (IC 50 = 5.8 μ M) that displays antisecretory and antiulcer activity. Inhibits gastric acid secretion (IC 50 = 0.16 μ M for histamine-induced acid formation) and reduces gastric lesion formation induced by a variety of ulcerative stimuli. Antibacteral against Helicobacter pylori in vitro . Also inhibits CYP2C19, CYP2C9 and CYP3A (K i values are 3.1, 40.1 and 84.4 μ M respectively) and blocks swelling-dependent chloride channels (ICIswell).
|
 |
Omeprazole
CAS: 73590-58-6
Assay: 98.5% min. CP
Packing: 20Kg/cardboard drum
MF: C17H19N3O3S
MW: 345.42
Character: White Crystalline Solid. mp 156°C. solubility H2O: 0.5 mg/mL
Usage: Binds covalently to proton pump. It inhibits gastric secretion. Used as an anttiulcerative pharmaceutical raw materials.
Biological Activity: H + ,K + -ATPase inhibitor (IC 50 = 5.8 μ M) that displays antisecretory and antiulcer activity. Inhibits gastric acid secretion (IC 50 = 0.16 μ M for histamine-induced acid formation) and reduces gastric lesion formation induced by a variety of ulcerative stimuli. Antibacteral against Helicobacter pylori in vitro . Also inhibits CYP2C19, CYP2C9 and CYP3A (K i values are 3.1, 40.1 and 84.4 μ M respectively) and blocks swelling-dependent chloride channels (ICIswell).
|
|
|
|
|
|
